§
Luxuse
Patent Intelligence
Sign In
← Back to Patent Explorer
US5861382A Expired / Lapsed US ⏱️ 0.0 years remaining

Methods for regulation of active TNF-α

Assignee: Yeda Research and Development Co Ltd
•
Filing: 1993-11-09
•
Granted: 1999-01-19
•
Expires: 2013-11-09
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Substances comprising disaccharides and substances comprising carboxylated and/or sulfated oligosaccharides in substantially purified form, and methods of using same, are disclosed for the regulation of cytokine activity in a host. For instance, the secretion of active Tumor Necrosis Factor Alpha (TNF-α) can be either inhibited or augmented selectively by administration to the host of an effective amount of a substance of the invention. Thus, the present invention also relates to pharmaceutical compositions and their use for the prevention and/or treatment of pathological processes involving the induction of active cytokine secretion, such as TNF-α. The invention also relates to the initiation of a desirable immune system-related response by the host to the presence of activators, including pathogens. The substances and pharmaceutical compositions of the present invention may be administered daily, at very low effective doses, typically below 0.1 mg/kg human, or at intervals of tip to about 5-8 days, preferably once a week.

Inventors

  • 👤 Irun R. Cohen
  • 👤 Ofer Lider
  • 👤 Liora Cahalon
  • 👤 Oded Shoseyov
  • 👤 Raanan Margalit

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-28 15:53
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61K31/7024; A61K31/7016; C; C07; C07H; C07H11/00; Y; Y10; Y10S; Y10S530/00; Y10S530/868

Claims Analysis

Total Claims: 7
Claim 1
Independent Claim 90 words
A method of inhibiting production of active TNF-α in a subject comprising administering to said subject an effective amount of a pharmaceutical composition comprising a disaccharide of formula (I) or its pharmaceutically acceptable salt ##STR10## in which X 1 is hydrogen or sulfate; X 2 is hydrogen or sulfate; and X 3 is sulfate or acetyl, provided that if X 3 is sulfate, then at least one of X 1 or X 2 is sulfate and if X 3 is acetyl, then both X 1 and X 2 are sulfates.
Claim 2
Independent Claim 90 words
A method of inhibiting production of active TNF-α in a subject comprising administering to said subject an effective amount of a pharmaceutical composition comprising a disaccharide of formula (I) or its pharmaceutically acceptable salt ##STR10## in which X 1 is hydrogen or sulfate; X 2 is hydrogen or sulfate; and X 3 is sulfate or acetyl, provided that if X 3 is sulfate, then at least one of X 1 or X 2 is sulfate and if X 3 is acetyl, then both X 1 and X 2 are sulfates.
Claim 3
Dependent Claim 13 words
The method of claim 1 in which said pharmaceutical composition is administered daily.
Claim 4
Dependent Claim 13 words
The method of claim 1 in which said pharmaceutical composition is administered weekly.
Claim 5
Dependent Claim 16 words
The method of claim 1 in which said pharmaceutical composition is administered parenterally, orally or topically.
Claim 6
Independent Claim 52 words
A method of inhibiting production of active TNF-α in a subject comprising administering to said subject an effective amount of a compound selected from the group consisting of an N-sulfated 4-deoxy-4-en-iduronoglucosamine having at least one other sulfate group, an N-acetylated 4-deoxy-4-en-iduronoglucosamine having at least two sulfate groups, and pharmaceutically acceptable salts thereof.
Claim 7
Independent Claim 52 words
A method of inhibiting production of active TNF-α in a subject comprising administering to said subject an effective amount of a compound selected from the group consisting of an N-sulfated 4-deoxy-4-en-iduronoglucosamine having at least one other sulfate group, an N-acetylated 4-deoxy-4-en-iduronoglucosamine having at least two sulfate groups, and pharmaceutically acceptable salts thereof.

References Cited (Backward Citations)

US4401662A Cited
US4446314A Cited
US4774231A Cited
US4818816A Cited
US4607025A Cited
US4987223A Cited
US4801583A Cited
US4539398A Cited
US4943630A Cited
EP0114589A1 Cited
US4727063A Cited
US4933326A Cited
US4973580A Cited
US4889808A Cited
US5034520A Cited
WO1988005301A1 Cited
US4990502A Cited
US5010063A Cited
US4981955A Cited
WO1990003791A1 Cited
EP0375976A2 Cited
EP0394971A1 Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 2002-01-18 2002-07-20 2003-01-19 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2006-01-18 2006-07-20 2007-01-19 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2010-01-18 2010-07-20 2011-01-19 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag